If you have been diagnosed with Autosomal Dominant Polycystic Kidney Disease (ADPKD), you may qualify for a new clinical trial evaluating the safety and effectiveness of an investigational drug designed to slow the progression of ADPKD and decelerate the decline in kidney function.
FIND OUT IF YOU QUALIFY
You have been diagnosed with Autosomal Dominant Polycystic Kidney Disease (ADPKD) by a physician.
You are a man or woman between the ages of 18 and 50 years old.
You have been successfully managing your blood pressure with anti-hypertension medication for at least 30 days.
Your kidney disease is at risk for rapid progression.
Even if your conditions vary from those above, you may still qualify. Find out if you are eligible.
The objective of this clinical trial is to determine the effect of the trial drug on the rate of total kidney volume (TKV) growth and the rate of renal function decline in patients at risk of rapidly progressive Autosomal Dominant Polycystic Kidney Disease.
Additionally, the trial will determine the safety and tolerability of the trial drug.
This is a two-stage clinical trial. Some trial participants will receive the trial drug, while others will receive a placebo, an inactive “dummy” pill, sometimes referred to as a “sugar pill.”
Patients with PKD are encouraged to take the 60-second screener to see if they may qualify for this clinical trial.
Trial-related medication and medical care may be provided at no cost to patients who qualify.
Medical care will take place at local hospitals and research centers that specialize in the treatment of kidney disease, and care will be provided by board-certified physicians.
Patients who are under 18 years of age or older than 50—or those who are pregnant—do not qualify for the trial.
This web site is intended for U.S. audiences only.
This web site does not replace the informed consent process. This web site does not replace the advice of your doctor.